• Japanese
  • Korean
  • Chinese
Cover Image

China Blood Product Industry Report, 2012-2015

Abstract

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It's expected that China's plasma supply tension will be further eased after 2013.

According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months of 2012, China's total lot release volume of blood products was about 36.13 million bottles, an increase of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a decreased lot release volume, other products saw growing release volume. In particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012. However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer product varieties. The domestic market is still dominated by technically undemanding human serum albumin and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot release volume in 2012.

In order to ease the domestic shortage of blood products, China has allowed the import of human serum albumin and recombinant coagulation factor VIII in recent years. Human serum albumin imports have grown rapidly due to low prices. The lot release volume was 8.51 million bottles in the first ten months of 2012, occupying 47.5% of the lot release volume of such products (43.3% in 2011); Behring, Baxter, Instituto Grifols and Octapharma were top four companies by lot release volume. However, due to high prices and national policy restrictions, the import of recombinant coagulation factor VIII is very small, only Bayer and Baxter products were allowed to be imported as of the end of 2012.

‘China Blood Product Industry Report, 2012-2015’ covers the followings:

  • Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry;
  • Competition pattern, policy environment and import & export of China blood product industry;
  • Market supply & demand and competition pattern of eight categories of blood products including human serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China;
  • Development, operation, plasma stations and lot release volume of 12 local blood product producers in China.

As of the end of 2012, there were about 30 enterprises passing GMP certification and in normal operation, among them, only Hualan Bio, Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS, Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual plasma volume of over 300 tons. In 2012, the five enterprises accounted for 56.1% of China's total plasma volume, and about 30% of China's blood product market revenue.

Guangdong Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three under construction) in 2012, with a plasma volume of about 247 tons and blood product revenue of RMB 431 million. The company has held the largest lot release volume of rabies immunoglobulin in recent years. Jiangxi Boya, though occupying a small market share (1.8% in 2012 by sales), has seven plasma stations, with output and sales volume expected to be further enhanced in the future.

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

  • To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
  • To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
  • To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
  • To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
  • To help company to succeed in a competitive market, and understand the size and growth rate of any opportunity.

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Table of Contents

1. Profile of Blood Products

  • 1.1. Definition
  • 1.2. Classification
  • 1.3. Recombinant Blood Products
  • 1.4. Industry Chain
  • 1.5. Features

2. Overview of China Blood Products Industry

  • 2.1. Market Size
  • 2.2. Development Status
  • 2.3. Supply & Demand
    • 2.3.1. Supply
    • 2.3.2. Demand
  • 2.4. Market Competition
  • 2.5. Operating Environment
    • 2.5.1. International Market
    • 2.5.2. Policies
    • 2.5.3. Domestic Biopharmaceutical Market
  • 2.6. Import & Export

3. Blood Product Market Segments in China

  • 3.1. Human Albumin
    • 3.1.1. Supply & Demand
    • 3.1.2. Competition Pattern
    • 3.1.3. Prospects
  • 3.2. Human Immunoglobulin (pH4) for Intravenous Injection
    • 3.2.1. Supply & Demand
    • 3.2.2. Competition Pattern
  • 3.3. Coagulation Factor VIII
    • 3.3.1. Supply & Demand
    • 3.3.2. Competition Pattern
    • 3.3.3. Prospects
  • 3.4. Hepatitis B Immunoglobulin
    • 3.4.1. Supply & Demand
    • 3.4.2. Competition Pattern
  • 3.5. Human Immunoglobulin
    • 3.5.1. Supply & Demand
    • 3.5.2. Competition Pattern
  • 3.6. Human Prothrombin Complex
    • 3.6.1. Supply & Demand
    • 3.6.2. Competition Pattern
  • 3.7. Tetanus Immunoglobulin
    • 3.7.1. Supply & Demand
    • 3.7.2. Competition Pattern
  • 3.8. Rabies Immunoglobulin
    • 3.8.1. Supply & Demand
    • 3.8.2. Competition Pattern

4. Key Companies in China

  • 4.1. China Biologic Products Inc.
    • 4.1.1. Profile
    • 4.1.2. Operation
    • 4.1.3. Revenue Structure
    • 4.1.4. Clients and Suppliers
    • 4.1.5. R&D and Investment
    • 4.1.6. Shandong Taibang Biological Products Co., Ltd.
    • 4.1.7. Guiyang Qianfeng Biological Products Co., Ltd.
    • 4.1.8. Xi'an Hui Tian Blood Products Co., Ltd.
    • 4.1.9. Development and Prospects
  • 4.2. Hualan Biological Engineering Inc.
    • 4.2.1. Profile
    • 4.2.2. Operation
    • 4.2.3. Revenue Structure
    • 4.2.4. Gross Margin
    • 4.2.5. Clients and Suppliers
    • 4.2.6. R&D and Investment
    • 4.2.7. Blood Products
    • 4.2.8. Development and Prospects
  • 4.3. Shanghai RAAS Blood Products Co., Ltd.
    • 4.3.1. Profile
    • 4.3.2. Operation
    • 4.3.3. Revenue Structure
    • 4.3.4. Gross Margin
    • 4.3.5. Clients and Suppliers
    • 4.3.6. R&D and Investment
    • 4.3.7. Development and Prospects
  • 4.4. Beijing Tiantan Biological Products Co., Ltd.
    • 4.4.1. Profile
    • 4.4.2. Operation
    • 4.4.3. Revenue Structure
    • 4.4.4. Clients and Suppliers
    • 4.4.5. Gross Margin
    • 4.4.6. R&D and Investment
    • 4.4.7. Blood Products (Chengdu Ronsen Pharmaceutical Co., Ltd.)
    • 4.4.8. Development and Prospects
  • 4.5. Zhenxing Biopharmaceutical & Chemical Inc.
    • 4.5.1. Profile
    • 4.5.2. Operation
    • 4.5.3. Revenue Structure
    • 4.5.4. Gross Margin
    • 4.5.5. Clients and Suppliers
    • 4.5.6. R&D and Investment
    • 4.5.7. Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)
    • 4.5.8. Development and Prospects
  • 4.6. Jiangxi Boya Biopharmaceutical Co., Ltd.
    • 4.6.1. Profile
    • 4.6.2. Operation
    • 4.6.3. Revenue Structure
    • 4.6.4. Gross Margin
    • 4.6.5. Clients and Suppliers
    • 4.6.6. R&D and Investment
    • 4.6.7. Development and Prospects
  • 4.7. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
    • 4.7.1. Profile
    • 4.7.2. Blood Products
  • 4.8. CNBG Shanghai Institute of Biological Products
    • 4.8.1. Profile
    • 4.8.2. Blood Products
  • 4.9. Shanxi Kangbao Biological Product Co., Ltd.
    • 4.9.1. Profile
    • 4.9.2. Blood Products
  • 4.10. Green Cross
    • 4.10.1. Profile
    • 4.10.2. Blood Products
  • 4.11. Humanwell Healthcare (Group) Co., Ltd.
    • 4.11.1. Profile
    • 4.11.2. Operation
    • 4.11.3. Blood Products (Wuhan Zhongyuan Ruide Biological Products Co., Ltd.)
  • 4.12. Walvax Biotechnology Co, Ltd.
    • 4.12.1. Profile
    • 4.12.2. Operation
    • 4.12.3. Blood Products (Hebei Daan Pharmaceutical Co., Ltd.)

Selected Charts:

  • Basic Composition of Blood
  • Classification and Application of Blood Products
  • Comparison between Recombinant Blood Products and Conventional Blood Products
  • Classification and Comparison of Domestic and Foreign Recombinant Blood Products
  • Blood Product Industry Chain
  • China's Blood Product Market Size, 2003-2015E
  • Prices of Some Blood Products in China, 2013
  • Lot Release Volume of Blood Products in China (by Product), 2007-2012
  • China's Blood Product Structure (by Lot Release Volume), 2009-2012
  • China's Plasma Volume, 2002-2012
  • Plasma Station Distribution in China by Region, Jun 2013
  • Health Insurance Coverage of Mainstream Blood Products in China
  • Comparison between China and Developed Countries by Per Capita Consumption of Blood Products
  • Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2012
  • Comparison among Domestic Blood Product Producers by Product Line
  • Global Blood Product Structure
  • Blood Products Available in Foreign Markets
  • Ongoing Clinical Trials of New Indications in Foreign Countries
  • Global Producers of Blood Products
  • Main Policies for Blood Products in China
  • Industrial Sales Output Value and Total Profit of China's Biological and Biochemical Manufacturing Industry, 2008-2012
  • Human Serum Albumin Prices in China, 2003-2012
  • Domestic and Imported Human Serum Albumin in China (by Lot Release Volume), 2007-2012
  • Market Share of Major Producers of Human Serum Albumin in China (by Lot Release Volume), 2008-2012
  • Comparison between China and USA by Consumption of Human Immunoglobulin for Intravenous Injection, 2010
  • Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2012
  • Comparison between China and Other Countries by Price of Human Immunoglobulin (pH4) for Intravenous Injection
  • Market Share of Major Producers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2012
  • Lot Release Volume and Growth Rate of Coagulation Factor VIII in China, 2008-2012
  • Market Share of Human Coagulation Factor VIII Producers in China (by Lot Release Volume), 2008-2012
  • Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII
  • Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2012
  • Market Share of Major Hepatitis B Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012
  • Prices of Human Immunoglobulin in China by Dosage Form, 2013
  • Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2012
  • Market Share of Major Human Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012
  • Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2009-2012
  • Market Share of Human Prothrombin Complex Enterprises in China (by Lot Release Volume), 2008-2012
  • Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012
  • Market Share of Major Tetanus Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012
  • Lot Release Volume and Growth Rate of Rabies Immunoglobulin in China, 2008-2012
  • Market Share of Major Rabies Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012
  • Shareholding Structure of China Biologic Products, 2012
  • Revenue and Operating Income of China Biologic Products, 2007-2012
  • Revenue of China Biologic Products (by Product), 2011-2012
  • Revenue Structure of China Biologic Products (by Product), 2010-2012
  • Revenue Contribution and % of Total Revenue of China Biologic Products' Top Five Customers, 2008-2012
  • R&D Investment and % of Revenue of China Biologic Products, 2010-2012
  • New Products under Research by China Biologic Products, 2012
  • Lot Release Volume of Blood Products of Shandong Taibang, 2008-2012
  • Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011
  • Lot Release Volume of Blood Products of Xi'an Hui Tian, 2008-2012
  • Revenue and Operating Income of China Biologic Products, 2012-2015
  • Revenue and Total Profit of Hualan Biological Engineering, 2007-2012
  • Revenue of Hualan Biological Engineering (by Sector), 2007-2012
  • Revenue of Hualan Biological Engineering (by Product), 2007-2012
  • Revenue of Hualan Biological Engineering (by Region), 2007-2012
  • Gross Margin of Hualan Biological Engineering (by Sector), 2007-2012
  • Gross Margin of Hualan Biological Engineering (by Product), 2007-2012
  • Revenue Contribution and % of Total Revenue of Hualan Biological Engineering's Top Five Customers, 2007-2012
  • Procurement of Hualan Biological Engineering from Top Five Suppliers, 2007-2012
  • R&D Investment and % of Total Revenue of Hualan Biological Engineering, 2007-2012
  • Blood Product Types and Specifications of Hualan Biological Engineering
  • Plasma Collection Distribution of Hualan Biological Engineering, May 2013
  • Lot Release Volume of Blood Products of Hualan Biological Engineering, 2008-2012
  • Blood Product Revenue and Gross Margin of Hualan Biological Engineering, 2007-2012
  • Blood Product Revenue and Gross Margin of Hualan Biological Engineering (by Product), 2007-2012
  • Revenue and Operating Income of Hualan Biological Engineering, 2012-2015E
  • Plasma Station Distribution of Shanghai RAAS, 2012
  • Revenue and Operating Income of Shanghai RAAS, 2007-2012
  • Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2012
  • Revenue of Shanghai RAAS (by Product), 2007-2012
  • Revenue of Shanghai RAAS (by Region), 2007-2012
  • Gross Margin of Shanghai RAAS (by Product), 2007-2012
  • Revenue Contribution of Shanghai RAAS' Top Five Customers, 2007-2012
  • Name List and Revenue Contribution of Shanghai RAAS' Top Five Customers, 2012
  • Procurement of Shanghai RAAS from Top Five Suppliers, 2007-2012
  • R&D Costs and % of Revenue of Shanghai RAAS, 2007-2012
  • Revenue and Operating Income of Shanghai RAAS, 2012-2015E
  • Major Subsidiaries and Their Revenue and Net Income of Beijing Tiantan Biological Products, 2012
  • Revenue and Total Profit of Beijing Tiantan Biological Products, 2007-2012
  • Revenue of Beijing Tiantan Biological Products (by Sector), 2007-2012
  • Revenue of Beijing Tiantan Biological Products (by Region), 2007-2012
  • Gross Margin of Beijing Tiantan Biological Products (by Sector), 2007-2012
  • Procurement of Beijing Tiantan Biological Products from Top Five Suppliers, 2007-2012
  • Revenue Contribution and % of Total Revenue of Beijing Tiantan Biological Products' Top Five Customers, 2007-2012
  • Name List and Revenue Contribution of Beijing Tiantan Biological Products' Top Five Customers, 2012
  • R&D Costs and % of Revenue of Beijing Tiantan Biological Products, 2009-2012
  • Plasma Station Distribution of Beijing Tiantan Biological Products, 2012
  • Blood Product Revenue and Gross Margin of Beijing Tiantan Biological Products, 2007-2012
  • Lot Release Volume of Blood Products of Chengdu Ronsen and Tiantan Chongqing, 2008-2012
  • Revenue and Operating Income of Beijing Tiantan Biological Products, 2012-2015
  • Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2009-2012
  • Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012
  • Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Region), 2009-2012
  • Gross Margin of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012
  • Revenue Contribution of Zhenxing Biopharmaceutical & Chemical's Top Five Customers, 2009-2012
  • Name List and Revenue Contribution of Zhenxing Biopharmaceutical & Chemical's Top Five Customers, 2012
  • Procurement of Zhenxing Biopharmaceutical & Chemical from Top Five Suppliers, 2012
  • R&D Costs and % of Revenue of Zhenxing Biopharmaceutical & Chemical, 2009-2012
  • R&D Progress of Zhenxing Biopharmaceutical & Chemical, 2012
  • Plasma Volume of Shuanglin Bio-pharmacy, 2010-2012
  • Plasma Station Distribution of Shuanglin Bio-pharmacy, 2012
  • Blood Product Output, Sales Volume and Inventory of Zhenxing Biopharmaceutical & Chemical, 2011-2012
  • Lot Release Volume of Blood Products of Shuanglin Bio-pharmacy, 2008-2012
  • Blood Product Revenue and Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2009-2012
  • Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2012-2015E
  • Plasma Collection Volume of Jiangxi Boya Bio-pharmaceutical, 2008-2012
  • Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2009-2012
  • Revenue of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012
  • Lot Release Volume of Blood Products of Jiangxi Boya Bio-pharmaceutical, 2011-2012
  • Revenue of Jiangxi Boya Bio-pharmaceutical (by Region), 2009-2012
  • Gross Margin of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012
  • Revenue Contribution and % of Total Revenue of Jiangxi Boya Bio-pharmaceutical's Top Five Customers, 2009-2012
  • Name List and Revenue Contribution of Jiangxi Boya Bio-pharmaceutical's Top Five Customers, 2012
  • Procurement of Jiangxi Boya Bio-pharmaceutical from Top Five Suppliers, 2009-2012
  • R&D Costs and % of Revenue of Jiangxi Boya Bio-pharmaceutical, 2009-2012
  • Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2012-2015E
  • Plasma Station Distribution of Sichuan Yuanda Shuyang Pharmaceutical, 2012
  • Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2012
  • Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2012
  • Plasma Station Distribution of CNBG Shanghai Institute of Biological Products, 2012
  • Plasma Station Distribution of Shanxi Kangbao Biological Product, 2012
  • Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2012
  • Plasma Station Distribution of Green Cross China, 2012
  • Lot Release Volume of Blood Products of Green Cross China, 2008-2012
  • Revenue and Operating Income of Humanwell Healthcare, 2007-2012
  • Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Products, 2008-2012
  • Industrial Distribution of Walvax Biotechnology
  • Revenue and Operating Income of Walvax Biotechnology, 2007-2012
Show More
Pricing
Get Notified
Email me when related reports are published